PathAI Stock
HealthTechLooking to sell PathAI stock or options?
PathAI is the developer of an AI-driven research platform designed to enhance the precision and speed of cancer diagnosis and treatment. The platform leverages machine and deep learning algorithms on aggregated datasets to independently identify cancerous cells, thus allowing pathologists to diagnose cancer patients both quickly and accurately.
Notable investors include:
Other investors include:
General Atlantic Service, Waikit Lau, Camford Capital, Quest Diagnostics, Refactor Capital, DHVC, Mike Volpe, Innospark Ventures, Pillar VC, Nimble Partners.